

**REMARKS**

Claims 2 to 10 are pending in this application. Claim 1 has been canceled without prejudice or disclaimer and claims 2-7 and 9 have been amended herewith.

Claim 7 has been amended for clarity, in response to a rejection under 35 U.S.C. 112, second paragraph.

Claims 2 and 3 have been amended to be independent, incorporating the limitations of base claim 1.

Claims 4, 5 and 6 have been amended to depend from claim 2 or 3.

Claim 9 has been amended to depend from claim 7 or 8.

**Claims 7-10 are rejected under 35 U.S.C. 112, second paragraph, as indefinite.**

The rejection is overcome by the amendment to claim 7. Claim 7 has been amended as suggested by the Examiner on page 2 of the Office action.

**Claims 1 and 4-6 are rejected under 35 U.S.C. 102(b) as anticipated by Hirose et al. (U.S. Pat. No. 4,965,311).**

The rejection is overcome by the amendments to the claims. Claim 1 has been canceled. Claims 4-6 have been amended to each depend from claim 2 or 3. Claims 2 and 3 were indicated in the Office action to be allowable if rewritten in independent form, and Applicants have rewritten claims 2 and 3 to be independent.

Amendment under 37 CFR 1.111  
Hirosaki ANDO et al.

U.S. Patent Application S.N. 09/701,011  
Attorney Docket No. 001550

**Claims 1 and 4-6 are rejected under 35 U.S.C. 102(b) as anticipated by Yukimoto et al. (U.S. Pat. No. 5,063,270).**

The rejection is overcome by the amendments to the claims. Claim 1 has been canceled. Claims 4-6 have been amended to each depend from claim 2 or 3. Claims 2 and 3 were indicated in the Office action to be allowable if rewritten in independent form, and Applicants have rewritten claims 2 and 3 to be independent.

**Claims 1 and 4-6 are rejected under 35 U.S.C. 102(e) as anticipated by Kalinowski et al. (U.S. Pat. No. 6,130,306).**

The rejection is overcome by the amendments to the claims. Claim 1 has been canceled. Claims 4-6 have been amended to each depend from claim 2 or 3. Claims 2 and 3 were indicated in the Office action to be allowable if rewritten in independent form, and Applicants have rewritten claims 2 and 3 to be independent.

**Claims 2 and 3 are objected to as being dependent upon a rejected base claim.**

Claims 2 and 3 have been rewritten to be in independent form, incorporating the limitations of claim 1. Applicants assert that the scope of the claims is unchanged by this amendment.

**Claims 7-10 would be allowable if rewritten to overcome the rejections under 35 U.S.C. 112, second paragraph.**

Amendment under 37 C.F.R. 1.111  
Hiroshi ANDO et al.

U.S. Patent Application S.N. 09/701,011  
Attorney Docket No. 001550

Applicants have amended claim 7 to overcome the rejection under 35 U.S.C. 112, second paragraph, as discussed above. Claim 9 has been amended to depend from claim 7 or 8.


If, for any reason, it is felt that this application is not now in condition for allowance, the Examiner is requested to contact Applicants' undersigned Agent at the telephone number indicated below to arrange for an interview to expedite the disposition of this case.

Attached hereto is a marked-up version of the changes made by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

In the event that this paper is not timely filed, Applicants respectfully petition for an appropriate extension of time. Please charge any fees for such an extension of time and any other fees which may be due with respect to this paper, to Deposit Account No. 01-2340.

Respectfully Submitted,

ARMSTRONG, WESTERMAN & HATTORI, LLP

  
Daniel A. Geselowitz, Ph.D.  
Agent for Applicants  
Reg. No. 42,573

DAG/plb  
Atty. Docket No. **001550**  
Suite 1000, 1725 K Street, N.W.  
Washington, D.C. 20006  
(202) 659-2930




23850

PATENT TRADEMARK OFFICE


Enclosures: Version with markings to show changes made  
H. H. COVER, DAG Amendment 001550, amendment filed 7-1-02

VERSION WITH MARKINGS TO SHOW CHANGES MADE  
IN THE CLAIMS

incubated; (c) the curing agent composition according to claim 1, wherein the curing agent composition contains a non-phthalic acid ester phthalic anhydride, a phthalic acid ester structure in its molecule, and a bivalent tin based curing catalyst, wherein the hydrolyzable silyl group is represented by a general formula (1):



wherein each of  $R^1$  and  $R^2$  represents an alkyl group having from 1 to 20 carbon atoms, a cycloalkyl group having from 3 to 10 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an aralkyl group having from 7 to 20 carbon atoms or a triorganosiloxy group represented by  $R^3-SiO-R^4$  (the same alkyl group, cycloalkyl group or aralkyl group of  $R^3$  and  $R^4$  and the three  $R^3$  groups may be the same or different from one another) wherein when two or more of  $R^1$  and  $R^2$  are present, they may be the same or different from one another,  $X$  represents a hydrolyzable group wherein when two or more of  $X$  are present, they may be the same or different from one another,  $a$  is 0, 1 or 2,  $b$  is 0, 1 or 2, and  $p$  is a in the  $p$  numbers of a group represented by a general formula (2):



is not necessarily the same, and p is an integer of from 0 to 19, with the proviso that (total of a) + (b) + 1 is satisfied).

3. (Twice Amended) A curing agent composition according to claim 1 which comprises a hydrolyzable silyl group-containing compound (a), a non-phthalic acid ester based plasticizer (b) having no phthalic acid ester structure in its molecule, and a bivalent tin based curing catalyst (c), wherein at least one species of the hydrolyzable silyl group-containing compound (a) is an amino group-containing silane compound (c).

4. (Twice Amended) The curing agent composition according to claim 2 or 3, wherein the non-phthalic acid ester based plasticizer (b) is at least one compound selected from the group consisting of aliphatic dibasic acid esters, glycol esters, aliphatic esters, phosphoric acid esters, epoxy plasticizers, ester based plasticizers, polyether based plasticizers, polystyrenes, hydrocarbon based plasticizers, butadiene-acrylonitrile copolymers and chlorinated paraffins.

5. (Twice Amended) The curing agent composition according to claim 2 or 3, wherein the non-phthalic acid ester based plasticizer (b) is at least one compound selected from the group consisting of polyether based plasticizers and hydrocarbon based plasticizers.

6. (Twice Amended) The curing agent composition according to claim 2 or 3, wherein the bivalent tin based curing catalyst (c) is at least one species selected from the group consisting of tin octylate, tin naphthenate, tin stearate and tin Versatate.

7. (Twice Amended) A two-pack type curable composition comprising as the first part ~~which hardens when a base resin composition (A) comprising~~ which comprises (d) a curable organic polymer (d) having in its molecule a functional group that is crosslinkable by a reaction catalyzed ~~by in the presence of a bivalent tin based curing catalyst (e),~~ (f) an epoxy group-containing silane compound (ff) and (g) an epoxy compound (gg); the second part being a ~~is mixed with the~~ curing agent composition (B) ~~described in claim 1~~ comprising (a) a hydrolyzable silyl group-containing compound, (b) a non-phthalic acid ester-based plasticizer and (c) a bivalent tin curing catalyst.

9. (Twice Amended) The two-pack type curable composition according to claim 7 or 8, wherein the curable organic polymer (d) is at least one compound selected from the group consisting of polyoxyalkylene based copolymers, hydrocarbon based polymers, polyester based polymers, acrylic acid ester based polymers, graft polymers, polysulfide based polymers, polyamide based polymers, polycarbonate based polymers and diallyl phthalate based polymers.